Rosiglitazone and pioglitazone, members of the thiazolidinediones (TZDs), are classical drugs that have traditionally been used to treat insulin resistance in T2DM, and the effects of the two drugs have been mediated through binding the PPARγ and have acted as an agonist of PPARγ [7]. The gene discussed is PPARG; the disease is Insulin resistance.